AIMS/HYPOTHESIS: Atorvastatin exerts beneficial vascular effects in diabetes, but the underlying mechanisms are yet to be elucidated. The aim of the present study was to determine whether Rac-1 is involved in the effect of atorvastatin on oxidative stress and vascular dysfunction. MATERIALS AND METHODS: Using human aortic endothelial cells (HAECs) we evaluated the effect of high glucose levels on peroxide production by dihydrodichlorofluorescein and on Rac-1 activity using immunocytochemistry to detect Rac-1 translocation to the membrane. We evaluated vascular function, peroxide production by dihydroethidium and NADPH oxidase activity in vessels from atorvastatin-treated mice. Rac-1 activity was also assessed, both by immunoprecipitation of the Rac-p21-activated kinase complex and by analysis of Rac-1 translocation to the membrane. These experiments were also conducted in vessels infected with an adenoviral vector carrying a constitutively active mutant of Rac-1. RESULTS: In HAECs exposed to high glucose levels, atorvastatin prevented oxidative stress, and this protection was associated with impaired Rac-1 activation. This effect was also observed in a murine model of diabetes mellitus. More importantly, the addition of geranylgeranyl pyrophosphate (GGPP) blocked the effects of atorvastatin in both glucose-exposed HAECs and diabetic vessels. Atorvastatin failed to afford protection against vascular abnormalities in the presence of a constitutively active mutant of Rac-1. CONCLUSIONS/ INTERPRETATION: The results of this study demonstrate that the vascular antioxidant effect of atorvastatin in diabetes is mediated through inhibition of Rac-1 via a reduction in GGPP. Thus, selective Rac-1 inhibition should be considered in the design of novel pharmacological strategies to reduce the impact of diabetes mellitus on vascular function.
AIMS/HYPOTHESIS: Atorvastatin exerts beneficial vascular effects in diabetes, but the underlying mechanisms are yet to be elucidated. The aim of the present study was to determine whether Rac-1 is involved in the effect of atorvastatin on oxidative stress and vascular dysfunction. MATERIALS AND METHODS: Using human aortic endothelial cells (HAECs) we evaluated the effect of high glucose levels on peroxide production by dihydrodichlorofluorescein and on Rac-1 activity using immunocytochemistry to detect Rac-1 translocation to the membrane. We evaluated vascular function, peroxide production by dihydroethidium and NADPH oxidase activity in vessels from atorvastatin-treated mice. Rac-1 activity was also assessed, both by immunoprecipitation of the Rac-p21-activated kinase complex and by analysis of Rac-1 translocation to the membrane. These experiments were also conducted in vessels infected with an adenoviral vector carrying a constitutively active mutant of Rac-1. RESULTS: In HAECs exposed to high glucose levels, atorvastatin prevented oxidative stress, and this protection was associated with impaired Rac-1 activation. This effect was also observed in a murine model of diabetes mellitus. More importantly, the addition of geranylgeranyl pyrophosphate (GGPP) blocked the effects of atorvastatin in both glucose-exposed HAECs and diabetic vessels. Atorvastatin failed to afford protection against vascular abnormalities in the presence of a constitutively active mutant of Rac-1. CONCLUSIONS/ INTERPRETATION: The results of this study demonstrate that the vascular antioxidant effect of atorvastatin in diabetes is mediated through inhibition of Rac-1 via a reduction in GGPP. Thus, selective Rac-1 inhibition should be considered in the design of novel pharmacological strategies to reduce the impact of diabetes mellitus on vascular function.
Authors: M Brennan Harris; Michele A Blackstone; Sarika G Sood; Chunying Li; Jonathan M Goolsby; Virginia J Venema; Bruce E Kemp; Richard C Venema Journal: Am J Physiol Heart Circ Physiol Date: 2004-04-15 Impact factor: 4.733
Authors: L Virág; P Jagtap; E Szabó; J G Mabley; L Liaudet; A Marton; D G Hoyt; K G Murthy; A L Salzman; G J Southan; C Szabó Journal: Nat Med Date: 2001-01 Impact factor: 53.440
Authors: James B Meigs; Christopher J O'donnell; Geoffrey H Tofler; Emelia J Benjamin; Caroline S Fox; Izabela Lipinska; David M Nathan; Lisa M Sullivan; Ralph B D'Agostino; Peter W F Wilson Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321
Authors: G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood Journal: Br J Pharmacol Date: 2016-07-14 Impact factor: 8.739
Authors: Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; María Isabel Castiñeiras-Landeira; Sergio Raposeiras-Roubín; José R González-Juanatey; Ezequiel Alvarez Journal: Vasc Health Risk Manag Date: 2013-07-25
Authors: Tae Ik Chang; Hye-Young Kang; Kyung Sik Kim; Sun Ha Lee; Bo Young Nam; Jisun Paeng; Seonghun Kim; Jung Tak Park; Tae-Hyun Yoo; Shin-Wook Kang; Seung Hyeok Han Journal: PLoS One Date: 2014-10-02 Impact factor: 3.240